IPO Issue Details
Issue Price / Price Band₹73 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size1,600 Shares per Lot
Total Issue Size68,62,400 shares (aggregating up to ₹50.10 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital
Exchange / PlatformBSE SME
IPO TypeSME
Subscription OpenThu, 09 Mar 2023
Subscription CloseTue, 14 Mar 2023
Anchor AllotmentWed, 08 Mar 2023
Basis of AllotmentFri, 17 Mar 2023
Initiation of RefundsMon, 20 Mar 2023
Credit of Shares to DematTue, 21 Mar 2023
Listing DateWed, 22 Mar 2023
UPI Mandate Deadline2023-03-14
Application & Investment Details
Retail — Min (1 Lots)₹1,16,800 — 1,600 shares
Retail — Max (13 Lots)₹1,518,400 (13 Lots)
HNI — Min (2 Lots)₹2,33,600 — 3,200 shares
P/E Ratio (Pre-IPO)24.33x
Net Offer to Public65,18,400 shares (aggregating up to ₹47.58 Cr)
Reserved for Market Maker3,44,000 shares (aggregating up to ₹2.51 Cr)
Pre-IPO Promoter Holding95,46,998 shares
Post-IPO Promoter Holding1,29,86,998 shares
About Sudarshan Pharma Industries Ltd
Incorporated in 2008, Mumbai based Sudarshan Pharma Industries Limited (SPIL) has a contract manufacturing facility to source and supply generic formulations. It is also engaged in import & export activities, and supply of specialty chemicals, API (Active Pharmaceutical Ingredients), and Intermediates. Based on clients' specifications and requirements, they outsource the manufacturing facility from the suppliers in India and abroad.The generic products supplied by the company have a wide application in paint, food, pharma, and adhesive industry. The company is involved in a contract manufacturing facility, supply and outsource of medicines and pharma formulation to hospitals, NGO, government and healthcare institutes. SPIL has 50 pharma formulations which are supplied under the brand name in the form of tablets, ointment, capsules, and injectable.The company has its own sales force and distribution network in 5 states for ethical marketing of pharmaceutical formulation & products under the brand name in Indian and international markets. It also offers formulation development and QC services and provides customised solutions.The competitive strengths of the company are:1. Customer-centric and order-driven business model2. Wide range of product offerings3. Contract manufacturing facility arrangements4. Strong distribution, marketing, and sales network5. Diversified business operations
Objects of the Issue
Sudarshan Pharma Industries Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
To set up a dedicated manufacturing facility for Pharmaceutical Business
12.50
2
Distribution and Warehousing Centre‘s & Purchase of Corporate Office
4.50
3
Additional Working Capital
5.25
4
General Corporate Expenses
2.80
Shareholding & Lock-in
Pre-IPO Promoter Holding
95,46,998 shares
Post-IPO Promoter Holding
1,29,86,998 shares